Determination of Dabigatran Concentration in Human Plasma and Breast Milk
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk in amounts which can be harmful to the suckli...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Analytical Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2021/5949385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545928118009856 |
|---|---|
| author | F. Sidgwick A. Porter P. Ayuk F. Kamali A. Truemann |
| author_facet | F. Sidgwick A. Porter P. Ayuk F. Kamali A. Truemann |
| author_sort | F. Sidgwick |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk in amounts which can be harmful to the suckling baby. We have developed an accurate, sensitive, and specific assay for the quantitation of dabigatran in both human plasma and breast milk. This is particularly useful for the determination of the extent by which dabigatran is secreted into breast milk in relation to its systemic availability. Dabigatran was enriched from both matrices using solid-phase extraction prior to separation on a C8-RPLC column and detection using SRM on a QqTrap mass spectrometer. The assay was validated for specificity, sensitivity, linearity, precision, accuracy, and stability of the analyte in human plasma and breast milk. The lower limit of detection for dabigatran was 20 pg/ml in plasma and 75 pg/ml in breast milk. This assay will aid future studies for the measurement of dabigatran concentrations in human breast milk to help determine if dabigatran etexilate can safely be administered to breast-feeding women. |
| format | Article |
| id | doaj-art-73faacf6a1e34ac18ebe82d6f16d9c52 |
| institution | Kabale University |
| issn | 1687-8760 1687-8779 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Analytical Chemistry |
| spelling | doaj-art-73faacf6a1e34ac18ebe82d6f16d9c522025-02-03T07:24:23ZengWileyInternational Journal of Analytical Chemistry1687-87601687-87792021-01-01202110.1155/2021/59493855949385Determination of Dabigatran Concentration in Human Plasma and Breast MilkF. Sidgwick0A. Porter1P. Ayuk2F. Kamali3A. Truemann4Newcastle University Protein and Proteome Analysis (NUPPA), Newcastle Upon Tyne, UKNewcastle University Protein and Proteome Analysis (NUPPA), Newcastle Upon Tyne, UKNewcastle Upon Tyne Hospitals Foundation Trust, Newcastle Upon Tyne, UKTranslational and Clinical Research Institute, Newcastle University and Newcastle Upon Tyne Hospitals Foundation Trust, Newcastle Upon Tyne, UKNewcastle University Protein and Proteome Analysis (NUPPA), Newcastle Upon Tyne, UKVenous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk in amounts which can be harmful to the suckling baby. We have developed an accurate, sensitive, and specific assay for the quantitation of dabigatran in both human plasma and breast milk. This is particularly useful for the determination of the extent by which dabigatran is secreted into breast milk in relation to its systemic availability. Dabigatran was enriched from both matrices using solid-phase extraction prior to separation on a C8-RPLC column and detection using SRM on a QqTrap mass spectrometer. The assay was validated for specificity, sensitivity, linearity, precision, accuracy, and stability of the analyte in human plasma and breast milk. The lower limit of detection for dabigatran was 20 pg/ml in plasma and 75 pg/ml in breast milk. This assay will aid future studies for the measurement of dabigatran concentrations in human breast milk to help determine if dabigatran etexilate can safely be administered to breast-feeding women.http://dx.doi.org/10.1155/2021/5949385 |
| spellingShingle | F. Sidgwick A. Porter P. Ayuk F. Kamali A. Truemann Determination of Dabigatran Concentration in Human Plasma and Breast Milk International Journal of Analytical Chemistry |
| title | Determination of Dabigatran Concentration in Human Plasma and Breast Milk |
| title_full | Determination of Dabigatran Concentration in Human Plasma and Breast Milk |
| title_fullStr | Determination of Dabigatran Concentration in Human Plasma and Breast Milk |
| title_full_unstemmed | Determination of Dabigatran Concentration in Human Plasma and Breast Milk |
| title_short | Determination of Dabigatran Concentration in Human Plasma and Breast Milk |
| title_sort | determination of dabigatran concentration in human plasma and breast milk |
| url | http://dx.doi.org/10.1155/2021/5949385 |
| work_keys_str_mv | AT fsidgwick determinationofdabigatranconcentrationinhumanplasmaandbreastmilk AT aporter determinationofdabigatranconcentrationinhumanplasmaandbreastmilk AT payuk determinationofdabigatranconcentrationinhumanplasmaandbreastmilk AT fkamali determinationofdabigatranconcentrationinhumanplasmaandbreastmilk AT atruemann determinationofdabigatranconcentrationinhumanplasmaandbreastmilk |